{"id":"decitabine-injection","safety":{"commonSideEffects":[{"rate":"60-90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"20-40","effect":"Infection"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"20-40","effect":"Fatigue"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"20-30","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL1201129","moleculeType":"Small molecule","molecularWeight":"228.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Decitabine is a cytidine analog that inhibits DNA methyltransferase (DNMT), leading to hypomethylation of DNA. By reducing aberrant DNA methylation in myelodysplastic syndrome cells, it reactivates epigenetically silenced tumor suppressor genes, promoting cellular differentiation, growth arrest, and apoptosis. This mechanism restores normal gene expression patterns in dysplastic hematopoietic cells.","oneSentence":"Decitabine is a DNA methyltransferase inhibitor that reduces DNA methylation, reactivating silenced tumor suppressor genes and promoting differentiation and apoptosis in myelodysplastic cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:11.270Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myelodysplastic syndromes (MDS)"},{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT01861314","phase":"PHASE1","title":"Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-03","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia","enrollment":15},{"nctId":"NCT01627041","phase":"PHASE2","title":"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-16","conditions":"Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":178},{"nctId":"NCT03041688","phase":"PHASE1","title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-08","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":58},{"nctId":"NCT07493330","phase":"PHASE1, PHASE2","title":"Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03-23","conditions":"PTCL, Refractory","enrollment":86},{"nctId":"NCT06379360","phase":"PHASE2","title":"Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-11-01","conditions":"Acute Myeloid Leukemia","enrollment":77},{"nctId":"NCT05796570","phase":"PHASE2","title":"A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies","status":"RECRUITING","sponsor":"Franziska Wachter","startDate":"2023-04-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies","enrollment":37},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT04282187","phase":"PHASE2","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-03-24","conditions":"Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome","enrollment":25},{"nctId":"NCT03404193","phase":"PHASE2","title":"Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-01-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":235},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT07060001","phase":"PHASE2","title":"Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)","enrollment":112},{"nctId":"NCT07451912","phase":"PHASE1, PHASE2","title":"Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-15","conditions":"Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML","enrollment":29},{"nctId":"NCT03969446","phase":"PHASE1","title":"Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-05-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT07148947","phase":"PHASE2","title":"Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-03-02","conditions":"Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm","enrollment":27},{"nctId":"NCT07283094","phase":"PHASE1","title":"FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-02-03","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT04263181","phase":"","title":"AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-29","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":80},{"nctId":"NCT03358719","phase":"PHASE1","title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-03-27","conditions":"Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia","enrollment":8},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT06997094","phase":"PHASE1","title":"Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-23","conditions":"Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT05038592","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-04","conditions":"Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2","enrollment":64},{"nctId":"NCT03661307","phase":"PHASE1, PHASE2","title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-31","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":73},{"nctId":"NCT04874480","phase":"PHASE1","title":"Tegavivint for the Treatment of Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-27","conditions":"Recurrent Leukemia, Refractory Leukemia","enrollment":9},{"nctId":"NCT05201066","phase":"PHASE2","title":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":33},{"nctId":"NCT05184842","phase":"PHASE2","title":"Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-03-23","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":91},{"nctId":"NCT05564650","phase":"PHASE1","title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-12","conditions":"Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome","enrollment":6},{"nctId":"NCT04188405","phase":"PHASE2","title":"Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-17","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":20},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT03132454","phase":"PHASE1","title":"Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-25","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":32},{"nctId":"NCT04878432","phase":"PHASE2","title":"STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-17","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":39},{"nctId":"NCT00801489","phase":"PHASE2","title":"Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-04","conditions":"Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","enrollment":270},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT04697940","phase":"PHASE1, PHASE2","title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han weidong","startDate":"2021-04-15","conditions":"Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells","enrollment":33},{"nctId":"NCT02890329","phase":"PHASE1","title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-05","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related","enrollment":54},{"nctId":"NCT04482621","phase":"PHASE2","title":"Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial","status":"SUSPENDED","sponsor":"Johns Hopkins University","startDate":"2020-09-14","conditions":"COVID-19","enrollment":33},{"nctId":"NCT06499025","phase":"EARLY_PHASE1","title":"Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)","status":"ENROLLING_BY_INVITATION","sponsor":"BGI, China","startDate":"2024-02-01","conditions":"AML, t(8;21), Neoantigen","enrollment":16},{"nctId":"NCT00095784","phase":"PHASE2","title":"Decitabine in Treating Patients With Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-09-29","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":21},{"nctId":"NCT02650986","phase":"PHASE1, PHASE2","title":"Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2017-07-14","conditions":"Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma","enrollment":15},{"nctId":"NCT03009240","phase":"PHASE1","title":"Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-08-21","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT02257138","phase":"PHASE1, PHASE2","title":"Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-02-12","conditions":"Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":30},{"nctId":"NCT05222984","phase":"PHASE1","title":"Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-29","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":17},{"nctId":"NCT06572631","phase":"PHASE1","title":"Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2025-06-07","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT03063944","phase":"PHASE1","title":"STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-03-17","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":37},{"nctId":"NCT05586074","phase":"PHASE3","title":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2023-03-03","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":324},{"nctId":"NCT03017131","phase":"PHASE1","title":"Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2017-12-08","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":9},{"nctId":"NCT04277442","phase":"PHASE1","title":"Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT06651866","phase":"PHASE1","title":"Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-12-12","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT03092674","phase":"PHASE2, PHASE3","title":"Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-02","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia","enrollment":76},{"nctId":"NCT06741722","phase":"PHASE2","title":"Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-10-31","conditions":"AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06612944","phase":"PHASE2","title":"Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-11-12","conditions":"Myelodysplastic Syndromes, Adult","enrollment":40},{"nctId":"NCT02281084","phase":"PHASE2","title":"Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-07-06","conditions":"Myelodysplastic Syndromes","enrollment":65},{"nctId":"NCT05177731","phase":"PHASE3","title":"Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chen Suning","startDate":"2022-03-01","conditions":"AML, Adult, Chemotherapy Effect","enrollment":188},{"nctId":"NCT06316960","phase":"PHASE2","title":"Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-03-01","conditions":"AML, Childhood, Relapse/Recurrence, Refractory AML","enrollment":50},{"nctId":"NCT06297772","phase":"PHASE3","title":"Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-06-01","conditions":"AML, Adult","enrollment":220},{"nctId":"NCT04905810","phase":"PHASE2","title":"Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure","status":"RECRUITING","sponsor":"Brian Jonas","startDate":"2022-02-09","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT05524857","phase":"PHASE1","title":"Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)","status":"TERMINATED","sponsor":"Joseph Jurcic","startDate":"2022-01-28","conditions":"Myeloproliferative Neoplasm","enrollment":2},{"nctId":"NCT04113616","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Kartos Therapeutics, Inc.","startDate":"2019-09-25","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)","enrollment":70},{"nctId":"NCT06046313","phase":"PHASE2","title":"Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-10-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":120},{"nctId":"NCT01812252","phase":"PHASE2","title":"Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-08-19","conditions":"Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":50},{"nctId":"NCT03593915","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2018-08-29","conditions":"Myelodysplastic Syndromes (MDS)","enrollment":20},{"nctId":"NCT04146038","phase":"PHASE2","title":"Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-10-26","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells","enrollment":5},{"nctId":"NCT01420926","phase":"PHASE2","title":"Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Therapy-Related Acute Myeloid Leukemia","enrollment":165},{"nctId":"NCT05638984","phase":"PHASE2","title":"Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"PFS","enrollment":60},{"nctId":"NCT03709550","phase":"PHASE1, PHASE2","title":"Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer","status":"WITHDRAWN","sponsor":"Roswell Park Cancer Institute","startDate":"2021-04-15","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":""},{"nctId":"NCT01834248","phase":"PHASE1","title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2013-07-30","conditions":"Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":9},{"nctId":"NCT05426798","phase":"PHASE1","title":"Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-04-29","conditions":"Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":73},{"nctId":"NCT04655391","phase":"PHASE1","title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2022-06-25","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT03217838","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2017-07-31","conditions":"Acute Myeloid Leukaemia","enrollment":50},{"nctId":"NCT03080766","phase":"PHASE2","title":"The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2017-03-01","conditions":"Acute Myeloid Leukemia, Complex Karyotype","enrollment":20},{"nctId":"NCT04493099","phase":"PHASE1, PHASE2","title":"Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-10","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT04611711","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors","status":"UNKNOWN","sponsor":"Peking University","startDate":"2020-11-01","conditions":"Patients With Digestive System Tumors Resistant to PD-1 Inhibitors","enrollment":60},{"nctId":"NCT04541277","phase":"PHASE2","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease","enrollment":55},{"nctId":"NCT04446130","phase":"PHASE3","title":"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-01-01","conditions":"Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia","enrollment":100},{"nctId":"NCT02921061","phase":"PHASE1, PHASE2","title":"Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-11-17","conditions":"Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT04292769","phase":"PHASE3","title":"Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors","status":"UNKNOWN","sponsor":"Li Yu","startDate":"2020-01-21","conditions":"Malignant Neoplasm","enrollment":200},{"nctId":"NCT01258868","phase":"PHASE1","title":"Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-01","conditions":"Mesolthelioma, Esophageal Cancer, Lung Cancer","enrollment":44},{"nctId":"NCT02129101","phase":"PHASE1","title":"Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-05","conditions":"Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia","enrollment":63},{"nctId":"NCT04087967","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":162},{"nctId":"NCT04083911","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":50},{"nctId":"NCT02634827","phase":"PHASE2","title":"Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-12-30","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, FLT3 Tyrosine Kinase Domain Point Mutation","enrollment":1},{"nctId":"NCT04026269","phase":"PHASE1, PHASE2","title":"Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen","status":"UNKNOWN","sponsor":"Han weidong","startDate":"2019-07-30","conditions":"Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT03146871","phase":"PHASE2","title":"Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2017-04-20","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome","enrollment":7},{"nctId":"NCT00416598","phase":"PHASE2","title":"Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-11-15","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11","enrollment":546},{"nctId":"NCT01729845","phase":"PHASE1, PHASE2","title":"Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2012-12-20","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia","enrollment":52},{"nctId":"NCT00085293","phase":"PHASE2","title":"Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-05","conditions":"Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer","enrollment":12},{"nctId":"NCT00791271","phase":"PHASE1","title":"Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-09-02","conditions":"Melanoma","enrollment":17},{"nctId":"NCT00321711","phase":"PHASE2","title":"Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-10-01","conditions":"MDS, Myelodysplastic Syndromes, Thrombocytopenia","enrollment":69},{"nctId":"NCT03701451","phase":"PHASE1, PHASE2","title":"Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Wei Jiang","startDate":"2018-02-28","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT03687463","phase":"","title":"Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia","status":"UNKNOWN","sponsor":"Capital Research Institute of Pediatrics","startDate":"2015-04-10","conditions":"Hematopoietic System--Cancer","enrollment":6},{"nctId":"NCT02121418","phase":"NA","title":"Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm","status":"COMPLETED","sponsor":"University of Washington","startDate":"2014-06","conditions":"Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myeloproliferative Neoplasm","enrollment":12},{"nctId":"NCT03381781","phase":"PHASE2","title":"Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations","status":"UNKNOWN","sponsor":"Li Junmin","startDate":"2018-03","conditions":"Acute Myeloid Leukemia, P53 Mutation","enrollment":100},{"nctId":"NCT01130506","phase":"PHASE1","title":"Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-05-17","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":17},{"nctId":"NCT02564536","phase":"PHASE1","title":"Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2017-06","conditions":"Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia","enrollment":""},{"nctId":"NCT01993641","phase":"PHASE2","title":"Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2013-12","conditions":"Myelodysplastic Syndrome, MDS","enrollment":45},{"nctId":"NCT01417767","phase":"PHASE2, PHASE3","title":"Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS","status":"UNKNOWN","sponsor":"Xiao Li","startDate":"2011-09","conditions":"Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT02845232","phase":"","title":"Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-03","conditions":"Acute Myeloid Leukemia","enrollment":214},{"nctId":"NCT01277484","phase":"PHASE1","title":"Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2011-01","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":19},{"nctId":"NCT01628471","phase":"PHASE1, PHASE2","title":"MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Uman Pharma","startDate":"2012-11","conditions":"Non Small Cell Lung Cancer","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"BONE MARROW FAILURE"},{"count":3,"reaction":"LUNG INFECTION"},{"count":3,"reaction":"NEUTROPENIA"},{"count":2,"reaction":"BACTERAEMIA"},{"count":2,"reaction":"BLOOD CULTURE POSITIVE"},{"count":2,"reaction":"HEPATIC FUNCTION ABNORMAL"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PNEUMONIA"},{"count":2,"reaction":"VOMITING"},{"count":2,"reaction":"WHITE BLOOD CELL COUNT DECREASED"}],"_approvalHistory":[],"publicationCount":68,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Decitabine","ASTX 727","tirelizumab","decitabine","DEC"],"phase":"marketed","status":"active","brandName":"decitabine injection","genericName":"decitabine injection","companyName":"Janssen Korea, Ltd., Korea","companyId":"janssen-korea-ltd-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Decitabine is a DNA methyltransferase inhibitor that reduces DNA methylation, reactivating silenced tumor suppressor genes and promoting differentiation and apoptosis in myelodysplastic cells. Used for Myelodysplastic syndromes (MDS), Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}